Cargando…

Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy

BACKGROUND: The phase II neo-adjuvant clinical trial ICORG10-05 (NCT01485926) compared chemotherapy in combination with trastuzumab, lapatinib or both in patients with HER2+ breast cancer. We studied circulating immune cells looking for alterations in phenotype, genotype and cytotoxic capacity (dire...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaynor, Nicola, Blanco, Alfonso, Madden, Stephen F., Moran, Barry, Fletcher, Jean M., Kaukonen, Damien, Ramírez, Javier Sánchez, Eustace, Alex J., McDermott, Martina S. J., Canonici, Alexandra, Toomey, Sinead, Teiserskiene, Ausra, Hennessy, Bryan T., O’Donovan, Norma, Crown, John, Collins, Denis M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491671/ https://www.ncbi.nlm.nih.gov/pubmed/37507543 http://dx.doi.org/10.1038/s41416-023-02375-y

Ejemplares similares

The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer
por: Eustace, A. J., et al.
Publicado: (2021)

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
por: Toomey, Sinead, et al.
Publicado: (2017)

Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
por: Cosgrove, Nicola, et al.
Publicado: (2023)

Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”
por: Keegan, Niamh M., et al.
Publicado: (2021)

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
por: McDermott, Martina SJ, et al.
Publicado: (2014)

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
por: Coté, Damien, et al.
Publicado: (2018)

Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
por: McDermott, Martina S. J., et al.
Publicado: (2023)

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells
por: McDermott, Martina S. J., et al.
Publicado: (2019)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Analysis of H3K4me3 and H3K27me3 bivalent promotors in HER2+ breast cancer cell lines reveals variations depending on estrogen receptor status and significantly correlates with gene expression
por: Kaukonen, Damien, et al.
Publicado: (2020)

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL
por: Eustace, Alex J, et al.
Publicado: (2018)

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer
por: Toomey, Sinead, et al.
Publicado: (2016)

Review of the status of neoadjuvant therapy in HER2-positive breast cancer
por: Dowling, Gavin P., et al.
Publicado: (2023)

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer
por: Elster, Naomi, et al.
Publicado: (2018)

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies
por: McDermott, Martina, et al.
Publicado: (2014)

Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
por: Mohd Sharial, M. S. N., et al.
Publicado: (2012)

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
por: O’Shea, John, et al.
Publicado: (2017)

Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo
por: Ding, Xiaokai, et al.
Publicado: (2022)

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
por: Mezynski, M. Janusz, et al.
Publicado: (2021)

Her Health, Common Dangers and Salvation
por: O'Donovan, W. J.
Publicado: (1918)

A gene expression profile indicative of early stage HER2 targeted therapy response
por: O’Neill, Fiona, et al.
Publicado: (2013)

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
por: Eustace, Alex J, et al.
Publicado: (2008)

Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer)
por: Falcon, Silvia, et al.
Publicado: (2022)

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer
por: Basho, Reva K., et al.
Publicado: (2018)

Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer
por: Walsh, Naomi, et al.
Publicado: (2020)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial
por: Gullo, Giuseppe, et al.
Publicado: (2019)

Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project
por: Gullo, Giuseppe, et al.
Publicado: (2018)

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2020)

Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer
por: Roche, Sandra, et al.
Publicado: (2023)

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
por: Horimoto, Yoshiya, et al.
Publicado: (2014)

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)
por: Tokunaga, Eriko, et al.
Publicado: (2021)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin
por: Mukherjee, Nupur, et al.
Publicado: (2022)

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
por: Press, Michael F., et al.
Publicado: (2018)

BreastMark: An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Cancer Outcome
por: Madden, Stephen F, et al.
Publicado: (2013)

Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?
por: Kavanagh, Dara O, et al.
Publicado: (2009)

Metastatic HER2+ Breast Cancer: A Potentially Curable Disease?
por: Prior, Lisa, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0k3pbckthq1c39grvro6t11hms